Advertisement

Journal of Robotic Surgery

, Volume 13, Issue 6, pp 747–756 | Cite as

Therapeutic supine robotic retroperitoneal lymph node dissection for post-chemotherapy residual masses in testicular cancer: technique and outcome analysis of initial experience

  • Ashwin Sunil Tamhankar
  • Saurabh Ramesh Patil
  • Surya Prakash Ojha
  • Puneet Ahluwalia
  • Gagan GautamEmail author
Original Article

Abstract

Retroperitoneal lymph node dissection (RPLND) is a therapeutic standard of care for post-chemotherapy residual masses in testicular cancer. While a robotic approach to this procedure has the potential of decreasing the morbidity associated with this major endeavour, it is often criticised for its inability to provide a bilateral complete template resection without redocking and repositioning the patient. Herein, we present the technique and initial outcomes of a supine approach to Robotic RPLND (R-RPLND) using the da Vinci Xi® system, which obviates the need for repositioning or redocking for a bilateral full template resection. Three patients (age 21–36) with nonseminomatous germ cell tumours of the testis underwent R-RPLND for post-chemotherapy residual retroperitoneal masses with normalised tumor markers. Salient steps of the procedure were as follows: port placement in supine Trendelenburg position, docking of the da Vinci Xi® system from one side, exposure of retroperitoneum, dissection of paracaval, retrocaval, interaortocaval, paraaortic and bilateral common iliac templates, and excision of gonadal vein. Mean console time and estimated blood loss were 257 (190–305) minutes and 333 (300–400) ml, respectively. Mean lymph node yield was 52 (29–94). One patient had a common iliac vein injury which was managed robotically without further consequence. No drains were placed in all three. There were no postoperative complications and all of them were advanced to a normal diet within 24 h and discharged on the second postoperative day. Histopathology reports were suggestive of necrosis and mature teratoma without any viable tumour. There have been no recurrences in these patients at a mean follow-up of 14 (1–22) months. R-RPLND in the supine position is practical, safe and feasible in the post-chemotherapy setting of testicular cancer. It eliminates the need for repositioning the patient or redocking the robot to achieve a complete resection with adequate lymph node yields, while preserving the benefits of a minimally invasive surgical approach.

Keywords

Retroperitoneal lymph node dissection Da Vinci Xi® system Post-chemotherapy residual masses in testicular cancer Robotic RPLND 

Notes

Compliance with ethical standards

Conflict of interest

Author Ashwin Sunil Tamhankar, Author Saurabh Patil, Author Surya Prakash Ojha, Author Puneet Ahluwalia and Author Gagan Gautam declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from all patients for being included in the study.

References

  1. 1.
    Gilligan T, Beard C, Carnerio B, Chism D, Cost N, Derweesh I et al Testicular cancer, version 2.2018, NCCN clinical practice guidelines in oncology. https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf. Accessed 30 May 2018
  2. 2.
    Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F et al (2008) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European germ cell cancer consensus group (EGCCCG): Part II. Eur Urol 53(3):497–513Google Scholar
  3. 3.
    Mosharafa AA, Foster RS, Leibovich BC, Bihrle R, Johnson C, Donohue JP (2003) Is postchemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol 169(6):2126–2128CrossRefGoogle Scholar
  4. 4.
    Stepanian S, Patel M, Porter J (2016) Robot-assisted laparoscopic retroperitoneal lymph node dissection for testicular cancer: evolution of the technique. Eur Urol 70(4):661–667CrossRefGoogle Scholar
  5. 5.
    Donohue JP (1977) Retroperitoneal lymphadenectomy: the anterior approach including bilateral suprarenal-hilar dissection. Urol Clin North Am 4(3):509–521PubMedGoogle Scholar
  6. 6.
    Cheney SM, Andrews PE, Leibovich BC, Castle EP (2015) Robot-assisted retroperitoneal lymph node dissection: technique and initial case series of 18 patients. BJU Int 115(1):114–120CrossRefGoogle Scholar
  7. 7.
    EAU Guidelines Edn. Presented at EAU Annual Congress Copenhagen (2018) ISBN 978-94-92671-01-1. http://uroweb.org/guideline/testicular-cancer/#12. Accessed 30 May 2018
  8. 8.
    Kamel MH, Littlejohn N, Cox M, Eltahawy EA, Davis R (2016) Post-chemotherapy robotic retroperitoneal lymph node dissection: institutional experience. J Endourol 30(5):510–519CrossRefGoogle Scholar
  9. 9.
    Singh A, Chatterjee S, Bansal P, Bansal A, Rawal S (2017) Robot-assisted retroperitoneal lymph node dissection: feasibility and outcome in post chemotherapy residual mass in testicular cancer. Indian J Urol 33(4):304–309CrossRefGoogle Scholar
  10. 10.
    Pooleri GK, Bijalwan P, Kesavan R, Philip A, Keechilat P (2018) Robot-assisted supine extraperitoneal retroperitoneal lymph node dissection: a novel approach for template dissection in post-chemotherapy residual mass in non-seminomatous germ cell tumours. J Robot Surg.  https://doi.org/10.1007/s11701-018-0810-9(Epub ahead of print) CrossRefPubMedGoogle Scholar
  11. 11.
    Lee SH, Kim DS, Chang SG, Jeon SH (2015) Robot-assisted laparoscopic retroperitoneal lymph node dissection for stage IIIb mixed germ cell testicular cancer after chemotherapy. Korean J Urol 56(7):540–544CrossRefGoogle Scholar
  12. 12.
    Overs C, Beauval JB, Mourey L, Rischmann P, Soulié M, Roumiguié M et al (2018) Robot-assisted post-chemotherapy retroperitoneal lymph nodedissection in germ cell tumor: is the single-docking with lateral approach relevant? World J Urol 36(4):655–661CrossRefGoogle Scholar
  13. 13.
    Bora GS, Panwar P, Mavuduru RS, Devana SK, Singh SK, Mandal AK (2017) Post chemotherapy retroperitoneal lymph node dissection in germ cell tumor: robotic way. J Robot Surg 11(2):279–285CrossRefGoogle Scholar
  14. 14.
    Stout TE, Soni SD, Goh AC (2016) Post-chemotherapy robotic bilateral retroperitoneal lymph node dissection using a novel single-dock technique. J Robot Surg 10(4):353–356CrossRefGoogle Scholar
  15. 15.
    Rukstalis DB, Chodak GW (1992) Laparoscopic retroperitoneal lymph node dissection in a patient with stage 1 testicular carcinoma. J Urol 148(6):1907–1909CrossRefGoogle Scholar
  16. 16.
    Davol P, Sumfest J, Rukstalis D (2006) Robotic-assisted laparoscopic retroperitoneal lymph node dissection. Urology 67(1):199CrossRefGoogle Scholar
  17. 17.
    Mosharafa AA, Foster RS, Koch MO, Bihrle R, Donohue JP (2004) Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol 171(5):1839–1841CrossRefGoogle Scholar
  18. 18.
    Janetschek G, Hobisch A, Hittmair A, Höltl L, Peschel R, Bartsch G (1999) Laparoscopic retroperitoneal lymphadenectomy after chemotherapy for stage IIBnonseminomatous testicular carcinoma. J Urol 161(2):477–481CrossRefGoogle Scholar
  19. 19.
    Permpongkosol S, Lima GC, Warlick CA, Allaf ME, Varkarakis IM, Bagga HS et a (2007) Post chemotherapy laparoscopic retroperitoneal lymph node dissection: evaluation of complications. Urology 69(2):361–365CrossRefGoogle Scholar
  20. 20.
    Palese MA, Su LM, Kavoussi LR (2002) Laparoscopic retroperitoneal lymph node dissection after chemotherapy. Urology 60(1):130–134CrossRefGoogle Scholar
  21. 21.
    Carver BS, Cronin AM, Eggener S, Savage CJ, Motzer RJ, Bajorin D et al (2010) The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. Urology 75(6):1431–1435CrossRefGoogle Scholar
  22. 22.
    Murilo A, Luz AF, Kotb S, Aldousari et al (2010) Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor. World J Surg Oncol 8:97CrossRefGoogle Scholar
  23. 23.
    Foster RS, Beck S, Bihrle R (2004) Secondary surgery in germ cell tumors—when and how extensively should it be performed? World J Urol 22(1):37–40CrossRefGoogle Scholar
  24. 24.
    Carver BS, Shayegan B, Eggener S, Stasi J, Motzer RJ, Bosl GJ et al (2007) Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of modified post chemotherapy retroperitoneal lymph node dissection. J Clin Oncol 25(28):4365–4369CrossRefGoogle Scholar
  25. 25.
    Ehrlich Y, Yossepowitch O, Kedar D, Baniel J (2006) Distribution of nodal metastases after chemotherapy in non seminomatous testis cancer: a possible indication for limited dissection. BJU Int 97(6):1221–1224CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Ltd., part of Springer Nature 2019

Authors and Affiliations

  1. 1.Max Institute of Cancer CareNew DelhiIndia

Personalised recommendations